La ligne téléphonique n’est pas disponible pour le moment.Pour toute demande veuillez envoyer un email a support@advfn.fr

European Health Regulators Approve Oral Treatment for Type 1 Diabetes

Date : 26/04/2019 @ 23h21
Source : Dow Jones News
Valeur : Sanofi (SNY)
Cours : 41.83  0.18 (0.43%) @ 01h59
Sanofi Cours Graphique

European Health Regulators Approve Oral Treatment for Type 1 Diabetes

Sanofi (NASDAQ:SNY)
Graphique Historique de l'Action

3 Mois : De Avr 2019 à Juil 2019

Plus de graphiques de la Bourse Sanofi

By Maria Armental

 

European health regulators have approved a pill that offers a chance to reduce the number of daily insulin injections for people with Type 1 diabetes, according to Sanofi SA and Lexicon Pharmaceuticals Inc.

Zynquista, which contains the active substance sotagliflozin, has been as a once-a-day pill to use with insulin therapy to help manage blood-sugar levels for those with a body mass index of at least 27.

U.S. health regulators last month rejected a similar application. Though the companies didn't specify the reason, a Food and Drug Administration advisory panel in January cast a split vote on whether Zynquista's benefits outweighed its risks.

Concerns focused on the "consistent and clinically meaningful increase in the risk of diabetic ketoacidosis," a life-threatening complication caused by a lack of insulin in the body, according to a panel report.

A similar panel in Europe also noted the higher risk of diabetic ketoacidosis but ultimately recommended approval.

Type 1 diabetes, which accounts for about 5% of all diagnosed cases of diabetes in the U.S., is an autoimmune condition caused by the body attacking itself and destroying the cells in the pancreas that make insulin.

The disease once was commonly referred to as insulin-dependent diabetes because it requires lifelong insulin therapy to manage blood-glucose levels.

Sanofi also is looking at sotagliflozin to treat the more prevalent Type 2 diabetes.

Shares in Lexicon are up 13% to $6.75 in after-hours trading, while American depositary receipts in Sanofi were flat. In regular trading, Lexicon shares rose 5.1% while Sanofi ADRs were up 3.4%.

 

Write to Maria Armental at maria.armental@wsj.com

 

(END) Dow Jones Newswires

April 26, 2019 17:06 ET (21:06 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Dernières Valeurs Consultées
EU
GLE
Société Gé..
EU
ALU
ALCATEL-LU..
EU
PX1
CAC 40
ORA
Orange
FX
EURUSD
Euro vs Do..
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.


Inscrivez-vous maintenant pour créer votre liste d'actions personnalisée, en streaming.

Les cours EURONEXT (CAC 40, etc. ) et FOREX (les devises) sont en direct si connecté.
NYSE, AMEX, et ASX sont en différé d'environ 20 minutes. Les autres cours sont en différé d'environ 15 minutes.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Conditions Générales

P: V:fr D:20190717 07:01:40